-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA Accepts Celcuity’s Revtorpyk Application for Expanded Breast Cancer Use

PUBT·11/09/2026 13:34:00
Listen to the news
FDA Accepts Celcuity’s Revtorpyk Application for Expanded Breast Cancer Use
  • FDA accepted Celcuity's supplemental application for Revtorpyk (gedatolisib) in HR+/HER2-negative, PIK3CA-mutated advanced breast cancer following progression on metastatic endocrine therapy.
  • The agency set a target decision date of June 25, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090830PRIMZONEFULLFEED9872988) on November 09, 2026, and is solely responsible for the information contained therein.